- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COA 2019: On Location Interviews, Day 2
On day 2 of the Community Oncology Alliance's annual Community Oncology Conference, held April 4-5 in Orlando, Florida, we spoke with Debra Patt, MD, MPH, MBA, executive vice president of Texas Oncology, and Jeffrey Vacirca, MD, chief executive officer of New York Cancer & Blood Specialists.
Today, we are on site for day 2 of the Community Oncology Alliance’s annual Community Oncology Conference in Orlando, Florida!
We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Debra Patt, MD, vice president of Texas Oncology, and Jeff Vacirca, MD, of New York Cancer & Blood Specialists.
Welcome to AJMC® on location, I’m Jaime Rosenberg!
The second day of the meeting focused on cancer drugs and different strategies for addressing their cost. There was a session on chimeric antigen receptor T-cell therapy, which explored different clinical and reimbursement challenges associated with the treatment. In addition, there were sessions on the adverse impact pharmacy benefit managers have on cancer care, and the effect of step therapy and utilization management on access to cancer treatments. We also got an industry perspective on price, cost, and value of cancer drugs.
Read coverage and watch additional interviews.
That’s all from COA's Annual Community Oncology Conference. Join us again May 19-21, when we will be reporting on site at The International Society for Pharmacoeconomics and Outcomes Research’s annual meeting being held in New Orleans, Louisiana.
Thank you for watching AJMC® News Network! I’m Jaime Rosenberg.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
